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The Pathology Workforce and Clinical
Licensure: The Role of the PhD Clinical
Laboratorian in the United States
Robin G. Lorenz, MD, PhD1 , Donald S. Karcher, MD2,
Michael D. Gautreaux, PhD3, Melvin Limson, PhD4 , and Dani S. Zander, MD5
Abstract
There has been a recent recognition of the need to prepare PhD-trained scientists for increasingly diverse careers in academia,
industry, and health care. The PhDData Task Forcewas formed to better understand the current state of PhD scientists in the clinical
laboratory workforce and collect up-to-date information on the training and certification of these laboratorians. In this report, we
summarize the findings of the PhDData Task Force and discuss the relevance of the data collected to the future supply of and demand
for PhD clinical laboratory scientists. It is clear that there are multiple career opportunities for PhD scientists in academic medical
centers, commercial clinical laboratories, biotechnology and pharmaceutical companies, and the federal government. Certified PhD
scientists have and will continue to form an important resource for our technologically advancing field, bringing training in scientific
methods, and technologies needed for modern laboratory medicine. The data gathered by the PhD Data Task Force will be of great
interest to current and future PhD candidates and graduate PhD scientists as they make decisions regarding future career directions.
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Introduction
The workforce of professionals involved in pathology, labora-
tory medicine, and clinical laboratory science has been the
subject of recent study. Much of this research has focused on
the number of pathologists currently in practice,1 the training of
new pathologists,2 the anticipated future demand for patholo-
gist services,3 and the potential shortage of pathologists in the
coming years.1 The clinical laboratory technologist workforce
has also been the subject of surveys and other studies.4 Less
work has been done to address the supply of and demand for
other members of the clinical laboratory team.5
In 2013, representatives of major pathology and laboratory
medicine professional organizations gathered to assess the cur-
rent state of the overall clinical laboratory workforce. The
Pathology Workforce Summit, held in December of 2013 and
cosponsored by the American Society for Clinical Pathology
(ASCP), Association of Pathology Chairs (APC), College of
American Pathologists (CAP), and United States and Canadian
Academy of Pathology (USCAP), involved a total of 24 pathol-
ogy and other medical organizations (Table 1). Following a full
day of live discussion, augmented by pre- and postmeeting
1 Department of Pathology, University of Alabama at Birmingham, Birmingham,
AL, USA
2 Department of Pathology, George Washington University, Washington, DC,
USA
3 Department of Pathology, Wake Forest School of Medicine, Winston-Salem,
NC, USA
4 Association of Pathology Chairs, Wilmington, DE, USA
5 Department of Pathology and Laboratory Medicine, University of Cincinnati,
Cincinnati, OH, USA
Corresponding Author:
Robin G. Lorenz, Department of Pathology, University of Alabama at
Birmingham, 1825 University Blvd., SHEL 121C, Birmingham, AL 35294, USA.
Email: rlorenz@uabmc.edu
Academic Pathology
Volume 5: 1–8
ª The Author(s) 2018
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/2374289518775948
journals.sagepub.com/home/apc
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License
(http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further
permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
exercises, participants reached consensus on a series of
workforce-related needs for the future (Table 2) and multiple
follow-up activities to support these needs. An executive sum-
mary of theWorkforce Summit and the Propositions can be found
at the following links: https://www.spponline.org/files/galleries/
WorkforceSummitExecSummary14-01.pdf; https://www.sppon
line.org/files/galleries/WorkforceSummitPropositions14-01.pdf.
One of the topics discussed during the Summit was the impor-
tant role that PhD clinical scientists play as members of the clin-
ical laboratory team. Formany years, PhD-trained scientists have
served as participants or leaders in various sections of clinical
laboratories and as clinical laboratory directors. Although these
roles are well established and many PhD scientists have received
special training and, in most cases, subspecialty certification for
this work, Summit participants agreed that there has never been a
comprehensive accountingof thePhDclinical laboratory scientist
workforce. Specifically, the number of PhD-trained scientists
currently engaged in clinical laboratory practice is unknown, and
there is no published national data on the number of PhD-holding
scientists who currently receive fellowship training and/or sub-
specialty certification each year in clinical laboratory disciplines.
To better understand the current state of the PhD clinical
laboratory scientist workforce and collect up-to-date informa-
tion on the training and certification of these laboratorians, the
PhD Data Task Force (PDTF) was formed as a follow-up to the
Pathology Workforce Summit. Managed by the APC and made
up of representatives of 8 pathology and clinical laboratory
organizations and 4 additional organizations involved in the
certification of PhD clinical laboratory scientists or accredita-
tion of clinical laboratories (Table 3), the PDTF has compiled
the most complete data set available, to date, on this important
component of the overall clinical laboratory workforce.
In this report, we summarize the findings of the PDTF and
discuss the relevance of the data collected to the future supply of
and demand for PhD clinical laboratory scientists. There has
been a recent recognition of the need to prepare PhD-trained
scientists for increasingly diverse careers in academia, industry,
and health care.6 The information gathered by the PDTF adds a
significant new data set that may help inform organizational
decisions and/or government policy regarding the future training
and/or certification of PhD scientists for work in the clinical
laboratory. These data will also potentially be of great interest
to current and future PhD candidates and graduate PhD scientists
as they make decisions regarding future career directions.
Table 1. Pathology Workforce Summit Participating Organizations.
Participating Organizations
Academy of Clinical Laboratory Physicians and Scientists (ACLPS)
Accreditation Council for Graduate Medical Education (ACGME)–
Pathology Residency Review Committee (RRC)
American Association of Neuropathologists (AAN)
American Board of Oral and Maxillofacial Pathology (ABOMP)
American Board of Pathology (ABP)
American Medical Association (AMA)
American Pathology Foundation (APF)
American Society for Clinical Pathology (ASCP)*
American Society for Investigative Pathology (ASIP)
American Society of Cytopathology (ASC)
American Society of Dermatopathology (ASD)
Association for Molecular Pathology (AMP)
Association for Pathology Informatics (API)
Association of American Medical Colleges (AAMC)
Association of Clinical Scientists (ACS)
Association of Directors of Anatomic and Surgical Pathology (ADASP)
Association of Pathology Chairs (APC)*
Canadian Association of Pathologists (CaAP)
College of American Pathologists (CAP)*
National Association of Medical Examiners (NAME)
Program Directors Section (PRODS) of APC
Society for Hematopathology (SH)
Society for Pediatric Pathology (SPP)
United States and Canadian Academy of Pathology (USCAP)*
* Summit cosponsors.
Table 2. Pathology Workforce Summit–Consensus Future Needs.
Workforce-related needs for the future
Better describe the work done by pathology and laboratory medicine
professionals to a variety of audiences (the public, policy makers,
medical students, each other, etc)
Recruit bright students into careers in pathology and laboratory
medicine
Train students and residents to be highly employable upon graduation
Assess whether the current paradigm for training pathologists needs
to be reformed, integrating residency, and fellowship training, to
meet the needs of employers and of new-in-practice pathologists
Keep a continuous, real-time cycle of review that allows periodic
assessment of evolving skills used in practice
Propagate an outlook of lifelong learning to maintain and enhance
career opportunities and applicability to current health-care
delivery systems and payment models
Table 3. PhD Data Task Force Participating Organizations.
Organization Names
Academy of Clinical Laboratory Physicians and Scientists (ACLPS)
American Board of Bioanalysis (ABB)
American Board of Clinical Chemistry (ABCC)–American Association
for Clinical Chemistry (AACC)*
American Board of Histocompatibility and Immunogenetics (ABHI)–
American Society for Histocompatibility and Immunogenetics
(ASHI)*
American Board of Medical Laboratory Immunology (ABMLI)–
American Society for Microbiology (ASM)*
American Society for Clinical Pathology (ASCP)
American Society of Cytopathology (ASC)
American Society for Investigative Pathology (ASIP)
Association for Molecular Pathology (AMP)
Association for Pathology Informatics (API)
Association of Clinical Scientists (ACS)
Association of Pathology Chairs (APC)
College of American Pathologists (CAP)–Laboratory Accreditation
Program (LAP)*
* Involved in certification of PhD clinical laboratory scientists or accreditation
of clinical laboratories.
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Background
Accreditation
Most clinical laboratories in the United States that test human
specimens for the diagnosis and treatment of patients fall under
the jurisdiction of the Clinical Laboratory Improvement
Amendments (CLIA). There are a few exceptions such as drug
testing laboratories for forensic or Department of Transporta-
tion testing, clinical trial testing, and government laboratories.
The CLIA sets the minimum standard for clinical laboratories
in the United States and is not limited to those laboratories
receiving Medicare payments. Although states may enact sta-
tutes that are more stringent than CLIA, laboratories subject to
CLIA must conform to both CLIA and state requirements.
The current form of CLIA was passed by the United States’
Congress as Public Law 100-578 in 1988 (https://www.gpo.gov/
fdsys/pkg/STATUTE-102/pdf/STATUTE-102-Pg2903 .pdf).
Originally proposed in the late 1960s, CLIA’67, and its update
CLIA’88, instituted standards for quality laboratory testing in the
United States. These public laws were incorporated into regula-
tions thatwere finalized in theCodeofFederalRegulations (CFR)
in 1972 and updated in 1992. Since then, there have been periodic
updates, all of which are published in the Federal Register.
The CLIA is administered by the Centers for Medicare and
MedicaidServices (CMS). Inaddition,other federal agencies such
as the Food and Drug Administration (FDA) and the Centers for
Disease Control and Prevention play roles in regulating how clin-
ical laboratories operate in the United States. The CMS is tasked
with enforcing regulatory compliance through conducting inspec-
tions for CLIA standards, approving private accreditation organi-
zations that perform inspections, or approving exempt states
(currently the only exempt states areWashington andNewYork).
The CMS deems various accrediting organizations (AOs) to
accredit laboratories forvarious specialtiesor subspecialties under
CLIA. The 7 CLIA-approvedAOs and the number of laboratories
in their programs are listed in Table 4. The specialties or subspe-
cialties that each AO can accredit can be found at www.cms.gov/
Regulations-and-Guidance/Legislation/CLIA/Downloads/AOS-
pecialtiesSubs.pdf. In addition to this list, some of the AOs
accredit laboratories for which CMS has not yet made a determi-
nationofCLIAcoverage.Some examples of these types of labora-
tories are embryology and molecular diagnostic laboratories.
Credentialing
Personnel requirements for CLIA—covered clinical laboratory
personnel are clearly outlined in the CLIA regulations.
Although accreditation is a laboratory-focused process, creden-
tialing an individual for a certain role in a clinical lab is a
person-focused process.
Credentialing can take 2 forms, either certification or licen-
sure. Certification is a process of recognition by a private certi-
fying board (Table 5). Certification by a CLIA-approved board
is based on education, experience, and knowledge (typically
judged by examination). Licensure is a state-by-state system that
defines, by statute, the tasks and function or scope of practice of
a profession and provides that these tasks may be legally per-
formed only by those who are licensed. As such, licensure pro-
hibits anyone from practicing the profession who is not licensed,
regardless of whether or not the individual has been certified by
a private organization. Of those states that have licensure, some
license the testing personnel (Medical Technologists and Med-
ical Laboratory Technologists) only, some only the director and/
or supervisor, and a few license both. However, the majority of
states do not license clinical laboratory personnel. Most states
use CLIA as the standard for qualifying personnel. Many
states that require licensure use certification or passing a cer-
tification examination offered by an accepted board as part of
their licensure requirements. Therefore, many individuals
hold both a license and a certification. Accrediting organiza-
tions, in part, use certification and licensure in determining
whether the laboratory personnel meet CLIA requirements as
part of the laboratory’s accreditation process.
Table 4. CLIA Deemed Accrediting Organizations.
Organization
Number of
Participating
Laboratories*
Commission on Laboratory Accreditation
(COLA)
6614
College of American Pathologists (CAP) 6237
The Joint Commission (TJC) 2209
American Association for Blood Banks (AABB) 202
American Osteopathic Association (AOA) 129
American Society for Histocompatibility and
Immunogenetics (ASHI)
101
American Association for Laboratory
Accreditation (A2LA)
Data not available
Abbreviations: CLIA, Clinical Laboratory Improvement Amendments; CMS,
Centers for Medicare and Medicaid Services.
* As reported by CMS to CLIAC November, 2016.
Table 5. CLIA-Deemed Certification Boards*.
Board Names
ABB–American Board of Bioanalysis
ABB public health microbiology certification
ABCC–American Board of Clinical Chemistry
ABFT–American Board of Forensic Toxicology (limited to individuals
with a doctoral degree)y
ABHI–American Board of Histocompatibility and Immunogenetics
ABMGG–American Board of Medical Genetics and Genomics
(formerly known as American Board of Medical Genetics (ABMG))
ABMLI–American Board of Medical Laboratory Immunology
ABMM–American Board of Medical Microbiology
NRCC–National Registry of Certified Chemists (limited to individuals
with a doctoral degree)y
Abbreviations: ABMGG, American Board of Medical Genetics and Genomics;
CLIA, Clinical Laboratory Improvement Amendments; NRCC, National
Registry of Certified Chemists.
*https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Certifi
cation_Boards_Laboratory_Directors.html
y These boards certify nondoctoral individuals also.
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The CLIA has defined 4 areas of complexity for laboratory
testing, with different personnel requirements, or credentials,
for each. The 4 test categories are: (a) waived, (b) provider-
performed microscopy (PPM), (c) moderate complexity, and
(d) high complexity. Waived tests are intended to employ
methodologies that are so simple and accurate as to render the
likelihood of erroneous results negligible; pose no reasonable
risk of harm to the patient if the test is performed incorrectly;
and have been cleared by the FDA. Examples include dipstick
urinalysis, fecal occult blood, urine pregnancy, and group A
Streptococcus antigen (Morbidity and Mortality Weekly
Report Reports and Recommendations https://www.cdc.gov/
mmwr/preview/mmwrhtml/rr5413a1.htm). No personnel
requirements are found in the CLIA regulations for waived
tests. All other categories are described as nonwaived. Non-
waived tests are categorized in section 493.17 of CLIA.
A grading system is used to determine whether a test is
moderate or high complexity. This system is outlined in sub-
section A of the CLIA regulations. In this system, each criter-
ion receives a score of 1, 2, or 3, with 1 being the lowest level of
complexity, and 3 indicating the highest level. If a test system
or assay receives an aggregate score of 12 or less, then it is
moderate complexity; scores greater than 12 are classified as
high-complexity tests (42 CFR 493.17). Examples of moderate
complexity tests are certain microbiological tests (such as bac-
terial culture, Gram staining, microscopic examination of cer-
tain slide preparations), urinalysis (such as osmolality or
sediments), hematology (eg, automated procedures, manual
white blood cell differential), and PPM such as analysis for
fecal leukocyte examination or nasal smears for eosinophils
(https://www.cdc.gov/mmwr/preview/mmwrhtml/00016177
.htm and https://www.cms.gov/Regulations-and-Guidance/Leg
islation/CLIA/Downloads/ppmplist.pdf). All other clinical
laboratory testing is referred to as high complexity, including,
but not limited to, immunohematology, chemistry, cytology,
histopathology, and histocompatibility.
The CLIA requirements differ for personnel who perform
PPM, moderate- and high-complexity testing and thus are
defined separately in 42 CFR 493 Subpart M. The regulations
specify qualifications for the various positions and also define
the functions and responsibilities for the persons who fill those
positions. Moderate complexity laboratories require the follow-
ing: (a) director, (b) technical consultant, (c) clinical consul-
tant, and (d) testing personnel. High-complexity laboratories
require the following: (a) director, (b) technical supervisor,
(c) clinical consultant, (d) general supervisor, and (e) testing
personnel. Persons who are qualified may perform the func-
tions of more than one position in either moderate- or high-
complexity testing. In other words, the same person may
function as both the laboratory director and the clinical consul-
tant or in some extreme cases, one person could qualify and
function in all of the positions listed. A doctoral degree is not
required to direct moderate complexity laboratories.
The remainder of this section will focus on high-complexity
testing. The information provided here for high-complexity per-
sonnel requirements will be limited to those entering the field
today. If an individual works in a state that requires licensure the
individual must meet that state’s licensure requirements and
maintain a current license in order to perform testing. Clinical
laboratory directors and clinical consultants entering the labora-
tory field today must have earned a clinical doctorate (MD, DO,
and DPM) or an earned doctoral degree (PhD, DSc) in a chem-
ical, physical, biological, or clinical laboratory science. If accep-
table to a CLIA-approved certifying board, the following
degrees may also be acceptable: Doctor of Dental Surgery
(DDS), Doctor of Dental Medicine (DMD), Doctor of Veterin-
ary Medicine (DVM), Doctor of Public Health (Dr PH). In addi-
tion, all nonphysician directors must become certified and
continue to be certified by a board approved by the US Depart-
ment of Health and Human Services (42 CFR 493.1443; Table
5). Physicians must be licensed to practice medicine in the state
in which they are serving as a director or clinical consultant.
MDs and DOs must also be certified in anatomic or clinical
pathology, or both, by the American Board of Pathology or the
American Osteopathic Board of Pathology or possess qualifica-
tions that are equivalent.7
Holders of other doctoral degrees (such as PhDs) must also be
certified and continue to be certified by a board approved by the
US Department of Health and Human Services (42 CFR
493.1443). The current approved boards are the following (Table
5): the American Board of Bioanalysis (ABB), the American
Board of Clinical Chemistry (ABCC), the American Board of
Forensic Toxicology (ABFT), the American Board of Histocom-
patibility and Immunogenetics (ABHI), the American Board of
Medical Genetics and Genomics (ABMGG), the American
Board of Medical Laboratory Immunology (ABMLI), the Amer-
ican Board of Medical Microbiology (ABMM), and the National
Registry of Certified Chemists (NRCC; https://www.cms.gov/
Regulations-and-Guidance/Legislation/CLIA/
Certification_Boards_Laboratory_Directors.html).
Certification requirements for the boards vary and there are
no national education requirements for curricula for PhD
laboratory directors. To be eligible to take the ABCC and
ABMM/ABMLI certification examination or be certified to
be an American Society for Histocompatibility and Immuno-
genetics (ASHI) director, postdoctoral fellows must complete 1
to 2 years in postdoctoral training programs approved by the
Commission for Accreditation in Clinical Chemistry
(ComACC), the Commission for Postdoctoral Education Pro-
grams (CPEP), or the ASHI, respectively.8-10 Candidates can
also sit for the ABCC examination with 5 years of experience.
Other boards, such as the ABB, require 4 years of experience, 2
of which must be at the supervisor or director level, to ensure
that an individual meets CLIA requirements and has the appro-
priate level of experience to be a director.
Results
AAMC Faculty Roster
One source of data to inform our understanding of the current
state of the PhD clinical laboratory scientist population in the
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clinical laboratory and pathology workforce is the Association
of American Medical Colleges (AAMC) Faculty Roster.11 The
Faculty Roster contains records on active, full-time faculty at
AAMC accredited allopathic US medical schools. As of April
2018, an average of 14.03% of US Medical School faculty in
clinical departments had PhDs or other health doctorates
(Figure 1). Perhaps not surprisingly, Pathology ranked third
in the percentage of PhD faculty members, with 25%. Although
these data indicate the significance of PhD scientists to the life
of academic departments, PhD scientists included in these fig-
ures play a variety of important roles in pathology departments,
with major contributions not only to the clinical workforce, but
also to the research and teaching missions of their departments.
However, it is important to keep in mind that academic med-
icine is only one small part of the clinical laboratory world.
College of American Pathologists (CAP) Laboratory
Accreditation Program
A second approach to determine the size of the PhD clinical
laboratory workforce is to evaluate the percentage of laboratory
directors with PhDs. In March 2017, the CAP Laboratory
Accreditation Program data indicated that in CAP-accredited
laboratories, 740 of 8356 (8.9%) Laboratory Directors have
PhDs (not including MD-PhDs, or DO-PhDs; Table 6). These
laboratory directors must have both an earned doctoral degree
and achieve board certification by ABB, ABCC, ABFT, ABHI,
ABMGG, ABMLI, ABMM, or NRCC. However, CAP accre-
dited laboratories represent less than half of the accredited
clinical laboratories (see Table 4). It is possible that other AOs
may accredit laboratories that have proportionately different
numbers of PhD directors.
National Science Foundation (NSF) Survey of Doctorate
Recipients (SDR)
The NSF SDR managed by the National Center for Science and
Engineering Statistics is a longitudinal biennial survey that pro-
vides statistical demographics about individuals with a research
doctoral degree (PhD) in science, engineering, or a health field
from a US academic institution (https://www.nsf.gov/statistics/
srvydoctoratework/). In the most recent data published (2013
survey cycle), occupations related to a “clinical laboratory” are
only broadly categorized, for example, “biological scientists,” or
“medical scientists.” Likewise, the sectors of employment are
even more broad, such as, “biochemistry/ biophysics,” “cell/
molecular biology,” or “microbiology.” Although the intent of
this biennial survey is to provide employment demographics and
statistics on the science and engineering workforce, this lack of
granular data limits the current usefulness of this survey to pro-
vide an accurate estimate of PhDs employed in the clinical
laboratory workforce.
National Certification
An alternative method to assess the size of the PhD clinical
laboratory workforce is to evaluate the number of board-
certified specialists in various clinical specialties that are com-
ponents of the clinical laboratory workforce. Several board
examinations exist to certify individuals with PhD (and MD)
degrees and these board are analogous to medical certifying
Psychiatry
Physical Medicine
Pathology (Clinical)
Ophthalmology
Radiology
Otolaryngology
Neurology
400 5 10 15 20 25 30 35
Dermatology
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Orthopedic Surgery
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Figure 1. The percentage of US Medical School faculty who had PhDs
or other health doctorates as reported by the AAMC Faculty Roster.
The AAMC Faculty Roster (https://www.aamc.org/data/facultyroster/
reports/486050/usmsf17.html) Table 6 was accessed on April 7, 2018
to determine the data shown. Other Health Doctorates are defined as
doctorates in dentistry, veterinary medicine, public health optometry,
and other health-related fields. This number does not include M.D./
PhD faculty. For the purposes of the AAMC Faculty Roster report,
faculty counts are broken out by department classification as opposed
to exact department name (ie, Radiation Oncology and Diagnostic
Radiology are both reported as “Radiology”).
Table 6. Degrees of the Clinical Laboratory Workforce as Deter-
mined by the College of American Pathologists (CAP) Laboratory
Accreditation Program*.
Role
PhD
PhD
Total
Non-
PhDy
Grand
Total
PhD
Only MD-PhD DO-PhD
Director 740 754 13 1507 6849 8356
Staff pathologist 161 2046 10 2217 17622 19 839
Consulting
pathologist
9 48 0 57 247 304
Administrator/
manager
255 15 1 271 6485 6756
Section director 2626 2987 41 5654 29 272 34 926
Supervisor 911 148 0 1059 29 161 30 220
Cosupervisor 395 53 1 449 10 251 10 700
QA contact/
manager
239 27 0 266 5457 5723
* These data are additive, meaning that every time the same person is identified
in a different role, different section of the same lab, and/or in a different
accredited lab, he/she is counted again, causing the numbers to be artificially
high. In other words, the numbers represent the number of times a PhD and/or
non-PhD is listed in any role in any accredited lab.
y“non-PhD” means a person with any degree (eg, MD, DO, BS, MS, etc) other
than a PhD.
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boards organized by the American Board of Medical Special-
ties. These certifications are recognized by various federal and
state agencies as necessary components to meet laboratory
licensure requirements. The results of our analysis are shown
in Table 7 for each of the deemed certifying boards (Table 5).
However, it should be cautioned that once again these data are
not complete or all inclusive.
The ABB is an international organization that certifies indi-
viduals as Technical Supervisors, Clinical Consultants, and
Directors in chemistry, diagnostic immunology, hematology,
microbiology, molecular biology (diagnostic), public health
microbiology, andrology, and embryology (https://www.aa
b.org/aab/American_Board_of_Bioanalysis.asp). The ABB has
indicated that of the 553 Director level diplomats, 86% are
PhD-only individuals. The ABCC is the national organization
that certifies individuals to practice clinical chemistry, toxico-
logical chemistry, and molecular diagnostics (http://www.ab
clinchem.org/). The ABCC register of active diplomates indi-
cates that there are 401 current active diplomates of which
336 (84%) are PhDs (Table 7). The ABMM and the American
Board of Medical Laboratory Immunologists (ABMLI; both
overseen by the American Society of Microbiology [ASM])
certify microbiologists and immunologists, respectively, to
direct clinical and public health laboratories (https://www.as-
m.org/index.php/professional-certification/abmm). There are
870 diplomates certified by ABMM and ABMLI, of which
527 (61%) are PhDs. The ASHI provides training and creden-
tialing for HLA Laboratory Directors. In the 7-year period
(2010-2016), there were 98 laboratory directors credentialed
of which 58 (59%) were PhD scientists. The ABMGG certifies
both MDs and PhDs in medical genetics and genomics. Sev-
eral of their specialty examinations are available to both MDs
and PhDs (http://abmgg.org/pages/training_options.shtml).
Although ABMGG does not provide a breakdown of the num-
ber of certified specialists by degree, there have been a total of
1788 specialists certified according to statistics extending
back to 1982 (http://abmgg.org/pages/resources_certspe
cial.shtml). These include 333 in Clinical Biochemical Genet-
ics, 770 in Clinical Cytogenetics and Genomics, and 685 in
Clinical Molecular Genetics and Genomics. It should be noted
that these numbers may be slightly higher than the actual
number of PhD Clinical Laboratorians, as some PhD may
have more than one certification.
Fellowship Programs
Fellowship programs are one way to train PhDs in clinical
laboratory sciences, and the other is on-the-job training. Fel-
lowship programs are postdoctoral training programs that pro-
vide curricula that include not only traditional testing in
clinical chemistry and/or microbiology/immunology but also
emerging fields of study. In order to evaluate the capacity for
training PhDs for the clinical laboratory workforce and for
passage of the certification examinations discussed above,
we evaluated the number of Clinical Chemistry Fellowship
programs accredited by the ComACC, the number of Micro-
biology/Immunology Fellowship programs accredited by
ASM/CPEP, and the number of Histocompatibility and
Immunogenetics ASHI-approved Fellowship programs avail-
able for training of PhD graduates. These are postdoctoral
training programs that provide curricula that include not only
traditional testing in clinical chemistry, microbiology/immu-
nology, and/or histocompatibility and immunogenetics but
also emerging fields of study.12 As of 2015, there were 20
ASM/CPEP accredited programs (17 that focused on Micro-
biology and 3 on Immunology), 32 ComACC accredited
programs (30 in United States and 2 in Canada), and 7
ASHI-approved programs (Table 8). These programs have
graduated a total of 164 fellows (68 in microbiology/immu-
nology and 96 in clinical chemistry) over a 4-year span (2013-
2016). This averages approximately 30 new fellows entering
into the clinical laboratory workforce each year. However, as
these fellowship programs are open to both PhD and MD
postdoctoral trainees, this number will not be equivalent to
the actual number of PhD scientists entering this workforce
each year. Also, in August, 2017, the ABMLI will phase out
its certification examination, but will continue to do recerti-
fication and maintain an active list of Diplomates. The
ABMGG lists 44 accredited clinical laboratory training pro-
grams (24 in clinical biochemical genetics, 7 in laboratory
genetics and genomics, 43 in clinical cytogenetics and geno-
mics, and 42 in clinical molecular genetics and genomics).
The list can be found at http://abmgg.org/pages/training_
accredprog.shtml. However, it should be noted that this is not
Table 7. Total number of MD, MD/PhD, and PhDs Certified by
National Organizations (Current Through 2016).
Certifying
Board MD
MD/
PhD# PhD (%)
Unknown/
Other Total
ABB* 37 23 474 (86) 19 553
ABCC-Clinical
Chemistryy
18 10 258 (85) 17 303
ABCC-Toxicologyy 1 1 43 (91) 2 47
ABCC-Molecular
Diagnosticsy
11 4 35 (69) 1 51
ASM-ABMMz 144 18 433 (62) 109 704
ASM-ABMLI§ 25 5 94 (57) 42 166
ASHI-DTRC -
-
22 17 58 (59) 1 98
ABFT-Fellow - - 183 (100) - 183
Total: 258 78 1578 (75) 191 2105
Abbreviations: ABB, American Board of Bioanalysis; ABMM, American Board of
Medical Microbiology; ABMLI, American Board of Medical Laboratory Immu-
nology; ASHI, American Society for Histocompatibility and Immunogenetics.
*Director (High-complexity Clinical Laboratory Director [HCLD] & Bioanalyst
Clinical Laboratory Director [BCLD]) certifications only. There are additional
PhDs with nondirector certifications.
yActive Diplomates as of January 1, 2017 (http://www.abclinchem.org).
z17.8% International.
§8% International.
--Number of HLA Lab Directors credentialed by ASHI Director Training Review
and Credentialing Committee (ASHI-DTRC) from 2010 to 2016; Board Certi-
fications: D(ABHI), HCLD(ABB), ABMLI.
#ASM database can only track one degree per account; therefore, the number
of MD/PhD diplomates may be higher than documented.
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a comprehensive data set, and the difficulties in finding com-
prehensive data on these types of postdoctoral clinical labora-
tory fellowship training programs may be one of the reasons
that PhD scientists do not adequately consider directing clin-
ical laboratories as one of their career options.
National Associations
There are a number of national and international associations for
individuals who work within the clinical laboratory. The associa-
tions in many cases represent not only the workforce but labora-
tory owners as well. Their members form a very heterogeneous
group with regard to the field of laboratory medicine. They rep-
resent not onlymedical schools andmajor hospitals but also small
hospitals, independent laboratories, specialty laboratories, refer-
ence laboratories, niche laboratories such as molecular, embryol-
ogy, and andrology laboratories, and emerging clinical laboratory
fields. All of these offer opportunities for the PhD scientist. In
fact, it is likely that directorship opportunities for PhDs are greater
in some of the areas outside of the medical school and large
hospital environment. Determining just where the greatest
opportunities are made more difficult by the lack of data main-
tained by many organizations involved in laboratory medicine.
Discussion
This article provides data regarding the scope of involvement
of PhD scientists in clinical laboratory oversight, and the path-
ways to preparation for careers in clinical laboratory medicine
and certification in clinical laboratory specialties. However,
defining the numbers of PhD scientists engaged in our clinical
laboratories has been more challenging. Our data indicate that
there are 3536 PhD scientists currently serving as Directors,
Section Directors, or Pathologists in clinical laboratories accre-
dited by CAP (Table 6). This is 5.6% of the total workforce in
these positions and this is potentially an underestimate, as these
data are only representative of a fraction of the laboratories
within the United States and because PhD scientists contribute
to our clinical laboratories in roles other than laboratory direc-
torships. Estimates of PhD workforce size could also be
derived from data about entry and attrition, but these data, to
our knowledge, are either not available (attrition) or incomplete
(entry). Nonetheless, the descriptive overview offered in this
article highlights organizations involved in the preparation of
PhD scientists for employment in clinical laboratories and pro-
vides insights into the training programs and certifying exam-
inations pursued by PhD graduates on the way to establishing
careers in clinical laboratory science and medicine.
Certifying examinations exist for most clinical laboratory dis-
ciplines, representing important milestones on the way to labora-
tory directorships (Table 5). These examinations offer an objective
approach tomeasuring knowledge and proficiency in one’s area of
specialization, and they are accepted components of meeting
CLIA-specifiedqualifications for laboratorydirectorship.Ourdata
indicate that there are only 1578 PhD scientists currently certified
by national organizations (Table 7). This is <50% of the number of
PhD scientists currently serving as Directors, Section Directors, or
Pathologists in CAP-accredited clinical laboratories, and would
appear to support the need for additional accredited training pro-
grams and training slots within the currently accredited programs.
There are currently only *34 CPEP (Microbiology) and 32
ComACC (Chemistry) positions available in any single year
(Table 8). However, one limitation to expansion of these programs
is funding. The current programs are usually supported by local
institutional/departmental funds. This is in contrast to Graduate
Medical Education for MDs (ie, residency/fellowship), which are
primarily supported by theUS government (Medicare). Since PhD
scientists are being trained and certified alongside MD clinicians,
one idea would be to make PhD clinical laboratory trainees also
eligible for this type of US government funding. Another innova-
tionmight be to cross-train PhD clinical laboratorians, so that they
have optimal job options (ie, havemultidisciplinary programs that
train in chemistry, microbiology, immunology, etc).
Training programs can represent an important pipeline of
PhD entrants into the world of the clinical laboratory. As dis-
cussed, accredited programs offered by ComACC, ASM/
CPEP, and ASHI provide educational experiences in clinical
chemistry, microbiology, immunology, and histocompatibility
and immunogenetics, which prepare PhD graduates for careers
in laboratory medicine. Although the numbers of graduates
from these programs are still relatively small, as needs for
well-trained PhD laboratory directors grow, the potential for
expansion of training opportunities exists.
One of the largest sources of information regarding potential
workforce opportunities available to PhDs may be the many
national organizations in the realm of laboratory medicine. How-
ever, the PhD scientist may not know of the existence of these
sources. Efforts need to be made to educate PhDs and Fellows
Table 8. Accredited Training Programs*.
Fellowship Program
Details
CPEP
(Immunology)
CPEP
(Microbiology) ComACCz
Total number accredited
programs
3 17 32
Typical program length 2 years 2 years 2 years
Average total number
applicants, per year*
138 689 NA
Average number
applicants per individual
program (2016)
40 40.5 NA
Average number positions
annually per program
1 (0-2) 2 (1-3) 1 (0-2)
Approximate percent of
positions filled in past
5 yearsy
95% 95% 86%
Number of graduates in
past 5 years (total)
8 60 96
Abbreviations: ComACC, Commission for Accreditation in Clinical Chemistry;
CPEP, Commission for Postdoctoral Education Programs.
*2013 to 2016; no data for CPEP Immunology in 2015.
yCalculated from the number of entering trainees (past 5 years) divided by the
total number of available slots (in all programs during the past 5-year period).
zThere were 53 active trainees as of July 1, 2016.
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about these sources of information during their training. National
organizations can offer many training opportunities through con-
ferences, workshops, hands-on workshops, seminars, webinars,
and online learning for the PhD scientist. In addition, they are an
excellent way to network with individuals already in the field
and to explore options available to the PhD scientist. These
organizations can spotlight the many, and diverse, opportunities
available to the PhD scientist outside of the medical school or
large hospital environment, many of which may offer greater
leadership options for the PhD scientist.
Expanding PhD graduates’ awareness of the excellent career
choices that exist in clinical laboratory science and medicine
represents a current need and opportunity. Many graduate
school curricula do not dedicate much time to introducing this
sector of career opportunities to students, and brief observa-
tional experiences may be the entire exposure that a student
receives to clinical laboratory medicine. Integrating more
information into these programs, either through curricular or
extracurricular experiences, could enhance interest in pursuing
a career direction that offers many advantages. In addition,
national organizations like the National Postdoctoral Associa-
tion (http://www.nationalpostdoc.org/) and the AAMC’s Group
on Graduate Research, Education, and Training (https://
www.aamc.org/members/great/) provide professional develop-
ment to and foster the exchange of information and ideas
among the faculty and administrative leaders of biomedical
PhD, MD/PhD and postdoctoral programs and would be excel-
lent partners to enhance the involvement of academic pathol-
ogy in order to inform trainees about certified training
opportunities in the clinical laboratory for PhDs.
Whether targeting PhD graduate students, postdoctoral fel-
lows, or faculty and administrators, a coordinated effort should
be made to promote and advocate for the career opportunities
available to PhD scientists in clinical laboratory medicine.
These career opportunities exist in academic medical centers,
commercial clinical laboratories, biotechnology and pharma-
ceutical companies, and the federal government. PhD scientists
will likely form an important resource for our technologically
advancing field, bringing training in scientific methods and
technologies needed for modern laboratory medicine. Their
integration into the laboratory workforce offers much to
enhance the future of Pathology and Laboratory Medicine.
Furthermore, strategies for collecting data and demographic
information on PhDs in the clinical laboratory setting should
be considered to provide a more complete and longitudinal
perspective on the PhD workforce.
Authors’ Note
A portion of these data was presented on April 22, 2017 at the XVII
Annual Workshop on Graduate Education in Pathology: PhD Clinical
Laboratory Scientist Workforce, Experimental Biology 2017,
Chicago, Illinois.
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